Last reviewed · How we verify
SHR1459
At a glance
| Generic name | SHR1459 |
|---|---|
| Also known as | Placebo, BTK inhibitor, No other intervention |
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy (PHASE2)
- An Open Label Study of the Effects of SHR1459 in NMOSDs Patients (PHASE2)
- A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects (PHASE1)
- Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor (PHASE1)
- A Bioavailability Study of SHR1459 on Healthy Chinese Volunteers (PHASE1)
- Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR1459 in Healthy Adult Male Volunteers (PHASE1)
- A Phase I Study of SHR1459 in Healthy Subjects (PHASE1)
- SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR1459 CI brief — competitive landscape report
- SHR1459 updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI